| Location: | Memphis, TN |
|---|
Sedgwick vice president of clinical pharmacy Paul Peak contributed to this article
Sedgwick's Paul Peak co-authored this article
An important judgement on opioids in Oklahoma While the country is still experiencing the devastating impact of a full-fledged opioid epidemic in 2019, the day may have arrived for a select group of drug manufacturers to face court-mandated restitut…
Sedgwick AVP of clinical pharmacy Dr. Paul Peak contributed to this article
Dr. Paul Peak contributed to this article
Claims administrators have an invaluable opportunity to help future pharmacists understand the challenges regarding prescription drug use for occupational injuries. A pharmacist intern program, like the one we offer at Sedgwick, can provide ex…
Sedgwick AVP, Clinical Pharmacy, Dr. Paul Peak notes the risk for addiction increases with longer first fills and comments on a trend for the drug management firms to help enforce the laws. Some physicians are still not listening to what is being re…
When it comes to getting the attention of the media and the public, not many things work better than an unfiltered, celebrity mugshot. When Tiger Woods was arrested on Memorial Day for driving under the influence, his mugshot and the story of his a…
Three weeks ago, I was wrapping up a discussion with a client and fellow Sedgwick colleagues on the opioid epidemic. Someone in the room received the unexpected text that Prince had died. In the next few moments, without any other information, my fel…
Last week, the Food and Drug Administration (FDA) made an extremely unique drug approval that was the first of its kind. In fact, it was one of the most revolutionary drug-related approvals seen in years. The FDA approved the first 3D printed drug,…
Topical compounds: amazing promises, high costs and unimpressive resultsAre we in Oz? BY PAUL PEAK, PHARMDDirector, Clinical Pharmacy, Complex Pharmacy Management, Sedgwick I was recently reminded of that famous moment in the Wizard of Oz and the lin…
On January 30, 2015 the Food and Drug Administration (FDA) approved a reformulated version of Zohydro ER (a long-acting, single-entity hydrocodone product) that is designed to possess abuse-deterrent properties. When the FDA originally approve…
